A six-week psychotherapy program, tailored specifically for people with neuromyelitis optica spectrum disorder (NMOSD) and delivered via telehealth, helped to ease anxiety and depression in adults with these conditions — with benefits lasting up to three months after treatment. These are the findings of a U.S. pilot clinical trial…
clinical trial
Bio-Thera Solutions has closed patient enrollment ahead of schedule for a pivotal Phase 2/3 clinical trial in China of its investigational therapy BAT4406F due to the treatment’s “compelling efficacy” for neuromyelitis optica spectrum disorder (NMOSD). The decision is based on a recommendation from an Independent Data Monitoring Committee…
HNSA-5487, Hansa Biopharma’s experimental treatment for neuromyelitis optica spectrum disorder (NMOSD) and other autoimmune diseases, safely and effectively reduced the levels of immunoglobulin G (IgG) antibodies — ones involved in the abnormal immune attacks that drive these conditions — in a Phase 1 clinical trial involving healthy volunteers.
A wearable neurostimulation device developed by NeuroMetrix is being investigated in a Phase 2 clinical trial as a potential pain-relieving treatment for people with neuromyelitis optica spectrum disorder (NMOSD). The trial (NCT04614454) is expected to recruit 46 adult NMOSD participants who test positive for aquaporin-4 antibodies and…
Recent Posts
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD
- When my invisible illness meets my very visible disabled parking spot
- Study IDs environmental factors tied globally to higher NMOSD risk
- Inflammatory protein S100A9 ID’d as new treatment target in NMOSD
- Connecting with others who have NMOSD gave me hope